Clinical Trial Update: Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325 [Phase 1]

View source ↗

Summary

A Phase 1 PET imaging study using 11C-flumazenil to measure central GABAA receptor occupancy by AZD7325 in individuals with anxiety; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety

Drugs mentioned

• AZD7325 (AZD7325)

Snippet

Sponsor: AstraZeneca | Conditions: Anxiety | Phase 1 | Status: COMPLETED